Early neoplastic progression is complement independent.
暂无分享,去创建一个
[1] J. Hodgson,et al. TIMP-1 Alters Susceptibility to Carcinogenesis , 2004, Cancer Research.
[2] P. Askenase,et al. B-1 B Cells Mediate Required Early T Cell Recruitment to Elicit Protein-Induced Delayed-Type Hypersensitivity 1 , 2003, The Journal of Immunology.
[3] R. López‐Ridaura,et al. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis , 2003, BMC Cancer.
[4] Alan D. Lopez,et al. Correction: Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000 , 2003, BMC Cancer.
[5] D. Hanahan,et al. Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells , 2003, The Journal of experimental medicine.
[6] V. Secor,et al. Cutting Edge: Both Activating and Inhibitory Fc Receptors Expressed on Mast Cells Regulate Experimental Allergic Encephalomyelitis Disease Severity 1 , 2003, The Journal of Immunology.
[7] L. Coussens,et al. Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. , 2002, Differentiation; research in biological diversity.
[8] Toshiaki Kawakami,et al. Regulation of mast-cell and basophil function and survival by IgE , 2002, Nature Reviews Immunology.
[9] Ruoyan Chen,et al. Macrophages, But Not T and B Lymphocytes, Are Critical for Subepidermal Blister Formation in Experimental Bullous Pemphigoid: Macrophage-Mediated Neutrophil Infiltration Depends on Mast Cell Activation1 , 2002, The Journal of Immunology.
[10] M. Wills-Karp,et al. Complement factor 3 mediates particulate matter-induced airway hyperresponsiveness. , 2002, American journal of respiratory cell and molecular biology.
[11] H. Jick,et al. Association Between Acetaminophen or Nonsteroidal Antiinflammatory Drugs and Risk of Developing Ovarian, Breast, or Colon Cancer , 2002, Pharmacotherapy.
[12] S. Weitzman,et al. Chronic inflammation and cancer. , 2002, Oncology.
[13] Y. Okayama,et al. IgG‐dependent activation of human mast cells following up‐regulation of FcγRI by IFN‐γ , 2001 .
[14] M. Cotterchio,et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[15] Rick A. Wetsel,et al. Cutting Edge: The Absence of C3 Demonstrates a Role for Complement in Th2 Effector Functions in a Murine Model of Pulmonary Allergy1 , 2001, The Journal of Immunology.
[16] Mina J. Bissell,et al. Putting tumours in context , 2001, Nature Reviews Cancer.
[17] M. Walport,et al. Complement. Second of two parts. , 2001, The New England journal of medicine.
[18] M. Walport. Complement. First of two parts. , 2001, The New England journal of medicine.
[19] L. Hansson,et al. Aspirin and risk for gastric cancer: a population-based case–control study in Sweden , 2001, British Journal of Cancer.
[20] John D Lambris,et al. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity , 2001, Immunological reviews.
[21] L. G. García Rodríguez,et al. Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs , 2001, Epidemiology.
[22] R. Ames,et al. Cutting Edge: Guinea Pigs with a Natural C3a-Receptor Defect Exhibit Decreased Bronchoconstriction in Allergic Airway Disease: Evidence for an Involvement of the C3a Anaphylatoxin in the Pathogenesis of Asthma1 , 2000, The Journal of Immunology.
[23] D. Hanahan,et al. MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.
[24] H. Kawamoto,et al. Correlation between Deposition of Immuno‐Components and Infiltration Pattern of Polymorphonuclear Leukocytes in the Lesions of Chronic Urticaria , 2000, The Journal of dermatology.
[25] R. DuBois,et al. The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.
[26] R. Ness,et al. Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.
[27] D. Hanahan,et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.
[28] P. Wolters,et al. Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. , 1999, Journal of immunology.
[29] D. Broide,et al. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. , 1999, Journal of immunology.
[30] J. Guitart,et al. Preferential activation of the complement system in the lower epidermis of patients with pemphigus vulgaris , 1998, The British journal of dermatology.
[31] H. Dvorak,et al. Mast Cells Can Secrete Vascular Permeability Factor/ Vascular Endothelial Cell Growth Factor and Exhibit Enhanced Release after Immunoglobulin E–dependent Upregulation of Fcε Receptor I Expression , 1998, The Journal of experimental medicine.
[32] P. Welker,et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. , 1998, Molecular biology of the cell.
[33] A. Andoh,et al. A blockade of complement activation prevents rapid intestinal ischaemia‐reperfusion injury by modulating mucosal mast cell degranulation in rats , 1998, Clinical and experimental immunology.
[34] S. Galli,et al. Impaired mast cell-dependent natural immunity in complement C3-deficient mice , 1997, Nature.
[35] T. Zuberbier,et al. C3a and C5a stimulate chemotaxis of human mast cells. , 1997, Blood.
[36] T. Halstensen,et al. Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. , 1997, Gut.
[37] D. Hanahan,et al. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. , 1996, The American journal of pathology.
[38] J. Ravetch,et al. A dominant role for mast cell Fc receptors in the Arthus reaction. , 1996, Immunity.
[39] G. Nilsson,et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. , 1996, Journal of immunology.
[40] P. Butko,et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[41] B. Jakschik,et al. The Role of Mast Cells and Their Mediators in IgG-Antigen Complex-Mediated Inflammation. , 1995, American journal of therapeutics.
[42] P. Norman. Immunobiology: The immune system in health and disease , 1995 .
[43] J. Ravetch,et al. Cytotoxic antibodies trigger inflammation through Fc receptors. , 1995, Immunity.
[44] G. Till,et al. The role of complement in experimental bullous pemphigoid. , 1995, The Journal of clinical investigation.
[45] J. Ravetch,et al. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. , 1994, Science.
[46] D. Hanahan,et al. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice , 1994, Journal of virology.
[47] D. Friend,et al. Strain-specific and tissue-specific expression of mouse mast cell secretory granule proteases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Troy,et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. , 1993, The Journal of clinical investigation.
[49] S. Weitzman,et al. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. , 1990, Blood.
[50] T. Halstensen,et al. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. , 1990, Gastroenterology.
[51] William Arbuthnot Sir Lane,et al. Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[52] H. Müller-Eberhard,et al. Release of histamine from rat mast cells by the complement peptides C3a and C5a. , 1975, Immunology.
[53] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.
[54] Y. Fujiyama,et al. Role of Complement Activation and Mast Cell Degranulation in the Pathogenesis of Rapid Intestinal Ischemia/Reperfusion Injury in Rats , 2001, Digestion.
[55] D. Metcalfe,et al. IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. , 2001, European journal of immunology.
[56] B. Gold,et al. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. , 2000, Annual review of microbiology.
[57] J A Hanley,et al. Nested caseÐcontrol study of the effects of non- steroidal anti-inflammatory drugs on breast cancer risk and stage , 2000 .